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Griscelli Syndrome Types 1 and 2
To the Editor:
In a recent report, Anikster et al. (2002) identified a
RAB27A (MIM 603868) deletion in a kindred with
Griscelli syndrome (GS) (MIM #214450). Several pa-
tients from this kindred displayed neurological manifes-
tations related to the hemophagocytic syndrome (HPS).
On the basis of their study, the authors suggest “that
the neurological involvement in these patients with GS
occurs secondarily to the hemophagocytic syndrome and
that patients with primary CNS complications and
MYO5A (MIM 160777) mutations have a related dis-
order, namely, Elejalde syndrome.” This assertion is cer-
tainly correct but surprisingly is presented as new and
as an “alternative explanation.” Several previously pub-
lished reports have unequivocally established that neu-
rological manifestations occurring in patients with GS
and caused by RAB27A mutation are related to lym-
phocyte infiltration of the CNS (Me´nasche´ et al. 2000;
Pastural et al. 2000; de Saint Basile and Fischer 2001),
whereas patient(s) with GS caused by MYO5A muta-
tions exhibit a primary neurological disease, potentially
described as Elejalde syndrome, and is unrelated to the
hematopoietic lineage, as also observed in Myo5a mu-
tant dilute mice (Pastural et al. 1997, 2000; Sanal et al.
2000; de Saint Basile and Fischer 2001; Ivanovich et al.
2001). The common finding of both conditions is al-
binism that results from the same mechanism—a defec-
tive release of melanosome content to neighboring cells,
such as keratinocytes in the skin. MyoVA and Rab27A
have been shown to interact in the same molecular path-
way, resulting in melanosome transport on actin filament
to dock at plasma membrane (Marks and Seabra 2001;
Hume et al. 2002; Provance et al. 2002; Seabra et al.
2002). There should not be any confusion left, since
patients with partial albinism and manifestations of
HPS, with or without neurological involvement, should
be screened for RAB27A mutations and treated accord-
ingly, whereas those with partial albinism and a primary
neurological disease without HPS should be screened for
MYO5A mutations, as discussed elsewhere (Me´nasche´
et al. 2000)
There are numerous examples of conditions grouped
under the same umbrella name (such as “Gaucher dis-
ease type I to III”) because of shared biological mech-
anisms, but that have different outcomes and treatments.
Griscelli syndromes 1 and 2 are other examples.
Incidentally, in table 1 of the Anikster et al. report,
the dilute and ashen murine models have been inverted,
potentially causing some confusion.
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Reply to Me´nasche´ et al.
To the Editor:
It is gratifying to learn that Me´nasche´ et al. (2002 [in
this issue]) agree with our analysis of the phenotypic
differences between patients with RAB27A mutations
and those with MYO5A mutations. We leave it to Jour-
nal readers to decide if previous publications have “un-
equivocally established” these points. We do apologize
for the error in table 1, which we recognized and have
corrected in an erratum.
Perhaps we could make two additional points. First,
Gaucher disease types I, II, and III represent examples
of defects in a single gene resulting in different pheno-
types, whereas Griscelli/Elejalde syndromes represent ex-
amples of defects in two different genes resulting in phe-
notypes with some similarities. Second, we wonder what
nomenclature should be employed for these two disor-
ders. Me´nasche´ et al. continue to use Griscelli syndromes
types 1 and 2. However, Griscelli’s original cases exhib-
ited immune deficiency (Griscelli et al. 1978), whereas
Elejalde first recognized a distinct, neurologically based
disorder (Elejalde et al. 1979). Perhaps Dr. Elejalde
should be credited for the accuracy of his ascertainment.
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Family-Based Association Tests Incorporating Parental
Genotypes
To the Editor:
The report “Parental Genotypes in the Risk of a Com-
plex Disease” (Labuda et al. 2002) gives several inter-
esting examples of how parental genotypes can contrib-
ute to children’s disease risk—for example, through
maternal effects during pregnancy or paternal effects
during spermatogenesis. The authors note that if disease
risk depends on parents’ genotypes but not their child’s
genotype, then the distribution of genotypes in cases will
not differ from the Mendelian expectation given their
parents’ genotypes. Hence, the traditional transmission
disequilibrium test (TDT) using case-parent trio data will
(correctly) not detect any association between individ-
uals’ genotypes and disease. The authors present an ex-
ample in which the TDT provides no evidence of an
association between a variant allele and disease (in fact,
the point estimate for the odds ratio is 1.0), whereas a
comparison of case subjects’ genotypes to those of pop-
ulation control subjects does provide evidence of asso-
ciation (estimated odds ratio p 3.4). The authors then
compare maternal and paternal genotypes to control
subjects’ genotypes and find evidence that the prevalence
of the variant allele is higher in parents of case subjects
than in population control subjects.
However, there are other analytic options in this
case—namely, flexible statistical methods for case-parent
trios which can test for parental-genotype effects. These
have the advantage of being robust to population-strat-
ification bias and, in some situations, are even more
powerful for testing for parental-genotype effects than
case-control studies (Starr et al. 2002).
The log-linear model developed by Weinberg et al. and
Wilcox et al. can test for parental-genotype and parent-
of-origin effects after adjusting for possible case-geno-
type effects (Weinberg et al. 1998; Wilcox et al. 1998).
In principle, this model can also test parental-genotype
# case-genotype interactions—which could be relevant;
